RATIONALE: The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signal transduction pathway has been implicated in some forms of learning and memory. Recent findings suggest that inhibition of phosphodiesterase (PDE) enzymes that degrade cGMP may have memory-enhancing effects. OBJECTIVES: We examined whether treatment with sildenafil citrate, a PDE type 5 inhibitor, would attenuate a learning impairment induced by inhibition of NO synthase [60 mg/kg N(omega)-nitro-L-arginine methyl ester (L-NAME), i.p.]. METHODS: Rats were pretrained in a one-way active avoidance of foot shock in a straight runway and, on the next day, received 15 training trials in a 14-unit T-maze, a task that has been shown to be sensitive to aging and impairment of central NO signaling systems. Combined treatments of L-NAME or saline and sildenafil (1.0, 1.5, 3.0, or 4.5 mg/kg, i.p.) or vehicle were given 30 and 15 min before training, respectively. Behavioral measures of performance included entries into incorrect maze sections (errors), run time from start to goal (latency), shock frequency, and shock duration. RESULTS: Statistical analysis revealed that L-NAME impaired maze performance and that sildenafil (1.5 mg/kg) significantly attenuated this impairment. Control experiments revealed that administration of L-NAME alone did not significantly increase latencies in a one-way active avoidance test and that different doses of sildenafil alone did not significantly alter complex maze performance. CONCLUSIONS: The results indicate that sildenafil may improve learning by modulating NO-cGMP signal transduction, a pathway implicated in age-related cognitive decline and neurodegenerative disease.
RATIONALE: The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signal transduction pathway has been implicated in some forms of learning and memory. Recent findings suggest that inhibition of phosphodiesterase (PDE) enzymes that degrade cGMP may have memory-enhancing effects. OBJECTIVES: We examined whether treatment with sildenafil citrate, a PDE type 5 inhibitor, would attenuate a learning impairment induced by inhibition of NO synthase [60 mg/kg N(omega)-nitro-L-arginine methyl ester (L-NAME), i.p.]. METHODS:Rats were pretrained in a one-way active avoidance of foot shock in a straight runway and, on the next day, received 15 training trials in a 14-unit T-maze, a task that has been shown to be sensitive to aging and impairment of central NO signaling systems. Combined treatments of L-NAME or saline and sildenafil (1.0, 1.5, 3.0, or 4.5 mg/kg, i.p.) or vehicle were given 30 and 15 min before training, respectively. Behavioral measures of performance included entries into incorrect maze sections (errors), run time from start to goal (latency), shock frequency, and shock duration. RESULTS: Statistical analysis revealed that L-NAME impaired maze performance and that sildenafil (1.5 mg/kg) significantly attenuated this impairment. Control experiments revealed that administration of L-NAME alone did not significantly increase latencies in a one-way active avoidance test and that different doses of sildenafil alone did not significantly alter complex maze performance. CONCLUSIONS: The results indicate that sildenafil may improve learning by modulating NO-cGMP signal transduction, a pathway implicated in age-related cognitive decline and neurodegenerative disease.
Authors: O P Dall'Igna; M O Dietrich; A Hoffmann; W Neto; D Vendite; D O Souza; D R Lara Journal: Eur J Pharmacol Date: 2001-11-30 Impact factor: 4.432
Authors: D K Ingram; E L Spangler; S Iijima; H Kuo; E L Bresnahan; N H Greig; E D London Journal: Ann N Y Acad Sci Date: 1994-06-30 Impact factor: 5.691
Authors: J C de la Torre; B A Pappas; V Prevot; M R Emmerling; K Mantione; T Fortin; M D Watson; G B Stefano Journal: Neurol Res Date: 2003-09 Impact factor: 2.448
Authors: M Cuadrado-Tejedor; I Hervias; A Ricobaraza; E Puerta; J M Pérez-Roldán; C García-Barroso; R Franco; N Aguirre; A García-Osta Journal: Br J Pharmacol Date: 2011-12 Impact factor: 8.739
Authors: Paul J Pistell; Chris M Nelson; Marshall G Miller; Edward L Spangler; Donald K Ingram; Bryan D Devan Journal: Behav Brain Res Date: 2008-08-22 Impact factor: 3.332
Authors: Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts Journal: Psychopharmacology (Berl) Date: 2008-08-16 Impact factor: 4.530
Authors: Donald C Goff; Corinne Cather; Oliver Freudenreich; David C Henderson; A Eden Evins; Melissa A Culhane; Jared P Walsh Journal: Psychopharmacology (Berl) Date: 2008-08-21 Impact factor: 4.530